Table 3.
Drug regimen and treatment duration of 1398 included patients categorized by treatment strategy
| Variable | 1398 cases | p value | ||
|---|---|---|---|---|
| Pharmaceutical care (n = 315) | Home visit (n = 559) | Modified DOT (n = 524) | ||
| Initial treatment regimen, n (%) | ||||
| 2HRZE/4HR | 309 (98.1) | 546 (97.7) | 517 (98.7) | 0.164a |
| 2HRZES/1HRZE/5HRE | 4 (1.3) | 13 (2.3) | 6 (1.1) | |
| Others | 2 (0.6) | 0 | 1 (0.2) | |
| Treatment duration, mean (SD) | ||||
| Duration of intensive phase, months | 2.5 (1.4) | 2.7 (1.1) | 2.5 (0.99) | 0.001b |
| Duration of continuation phase, months | 4.6 (2.2) | 5.2 (3.1) | 4.0 (1.4) | <0.001b |
ANOVA analysis of variance, DOT directly observed therapy, E ethambutol, H isoniazid, R rifampicin, S streptomycin, Z pyrazinamide
a Fisher’s Exact test
b One-way ANOVA